Literature DB >> 31587493

Acne treatment efficacy of intense pulsed light photodynamic therapy with topical licochalcone A, l-carnitine, and decanediol: A spilt-face, double-blind, randomized controlled trial.

Rungsima Wanitphakdeedecha1, Nudpanuda Tavechodperathum1, Ploypailin Tantrapornpong1, Panittra Suphatsathienkul1, Thanya Techapichetvanich1, Sasima Eimpunth1, Woraphong Manuskiatti1.   

Abstract

BACKGROUND: Depending on disease severity, standard acne treatments can vary from topical to systemic therapy. However, poor compliance caused by adverse events and antibiotic resistance is a major cause of treatment failure. AIMS: To determine the effectiveness of photodynamic therapy (PDT) with intense pulsed light (IPL) in the treatment of acne when combined with a cream containing licochalcone A, L-carnitine and decanediol (so-called, 'active formulation') versus PDT alone. PATIENTS/
METHODS: Twenty-nine volunteers, aged 21-39 years (26 women and 3 men, mean age 29.41 ± 5.24 years), with mild to severe facial acne, were enrolled. Each subject's face sides were randomized in a split-face manner to either receive PDT (IPL with a 400-720 nm cut-off filter, at 4 sessions with two-week intervals) combined with the active formulation cream twice daily for 10 weeks on one face side; or PDT and the vehicle cream on the other side, with the same treatment protocol. Reduction in acne quantity, melanin index and erythema index were assessed 2 weeks after the second treatment (day 28), 1 week after the fourth treatment (day 49), and 1 month after the fourth treatment (day 70).
RESULTS: Compared to baseline, patients in the active formulation group demonstrated a faster onset of reduction in the number of lesions at 2 weeks after the second treatment (p=0.010 for inflammatory acne and p=0.001 for non-inflammatory acne). A significantly greater reduction in lesion count was observed in the active formulation group compared with the vehicle group at all timepoints of evaluation for noninflammatory acne (day 28, day 49, and day 70; p=0.003, 0.005 and 0.002 respectively), and at 1 month after the fourth treatment for inflammatory acne (p=0.036). Compared to the vehicle group, the melanin index of the active formulation group decreased significantly at 1 month after the fourth treatment (p=0.015).
CONCLUSION: PDT is more effective in treating acne when combined with a topical cream containing licochalcone A, L-carnitine and decanediol, than PDT alone. Significant acne reduction and improvements in post-inflammatory hyperpigmentation were observed, which offers acne patients a better therapeutic option. It is a safe and effective combination treatment for patients with moderate and severe acne.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  acne; decanediol; intense pulsed light; l-carnitine; licochalcone A; photodynamic therapy

Year:  2019        PMID: 31587493     DOI: 10.1111/jocd.13178

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  3 in total

Review 1.  A Meta-analysis-Based Assessment of Intense Pulsed Light for Treatment of Melasma.

Authors:  Jiarong Yi; Tao Hong; Hanling Zeng; Peiwen Li; Pinglu Li; Shaohua Wang; Jia Chen; Ping Li; Jianda Zhou
Journal:  Aesthetic Plast Surg       Date:  2020-02-13       Impact factor: 2.326

2.  A Double-Blinded, Randomized, Vehicle-Controlled Study of the Efficacy of Moisturizer Containing Licochalcone A, Decanediol, L-Carnitine, and Salicylic Acid for Prevention of Acne Relapse in Asian Population.

Authors:  Kanokvalai Kulthanan; Suphattra Trakanwittayarak; Papapit Tuchinda; Leena Chularojanamontri; Pichaya Limphoka; Supenya Varothai
Journal:  Biomed Res Int       Date:  2020-10-16       Impact factor: 3.411

3.  Baicalin suppresses Propionibacterium acnes-induced skin inflammation by downregulating the NF-κB/MAPK signaling pathway and inhibiting activation of NLRP3 inflammasome.

Authors:  Fang Fang; Zeping Xie; Jingyu Quan; Xiaohan Wei; Linlin Wang; Liu Yang
Journal:  Braz J Med Biol Res       Date:  2020-10-21       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.